Last10K.com

Canopy Growth Corp (CGC) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2020

SEC Filings

Canopy Growth Corp

CIK: 1737927 Ticker: CGC

 

Exhibit 99.1

 

CANOPY GROWTH REPORTS SECOND QUARTER FISCAL 2021 FINANCIAL RESULTS

 

Achieved record quarterly net revenue of $135 million  

Net Loss of $97 million; Adjusted EBITDA loss of $86 million, a 43% improvement versus Q2 FY20

Implementing initiatives to capture $150-$200 million of savings across our cost structure

Increased market share by 200 basis points in Canadian recreational market based on our proprietary market share tracker

Building momentum in the U.S. and establishing foundation for long-term leadership position

November 9, 2020

SMITHS FALLS, ON — Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NYSE:CGC) today announced its financial results for the second quarter fiscal 2021 ended September 30, 2020.  All financial information in this press release is reported in millions of Canadian dollars, unless otherwise indicated.

“Our renewed strategy of winning consumer mindshare, along with increased agility and execution, has resulted in record net revenue for the second quarter and momentum across key areas of business,” said David Klein, CEO.  “Canopy Growth is positioned for continued growth as we establish a strong leadership position that is showcased through our vast portfolio of differentiated brands and products – including our industry leading cannabis-infused beverages.”

“We saw another quarter of improvement in our operating expense ratio while our marketing and R&D investments are being re-directed to drive sales,” added Mike Lee, CFO. “Importantly, our end-to-end review has identified cost savings opportunities in the range of $150-$200 million across cost of goods sold, general and administrative expenses, and inventory, and efforts are underway to quickly capture value.  Leveraging ongoing improvements across our business, we are accelerating our path to profitability, notably in our largest market, Canada.”

 

 

 

 


The following information was filed by Canopy Growth Corp (CGC) on Monday, November 9, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Canopy Growth Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Canopy Growth Corp.

Continue

Assess how Canopy Growth Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Canopy Growth Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
M & A
Financial
Legal
Revenue
Other
Filter Subcategory:
All
Expense
Income
Shares
Cash Flow
Geography
Product
Earnings
Debt
Other
Inside Canopy Growth Corp's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Interim Consolidated Balance Sheets (Parenthetical) (Unaudited)
Condensed Interim Consolidated Balance Sheets (Unaudited)
Condensed Interim Consolidated Statements Of Cash Flows (Unaudited)
Condensed Interim Consolidated Statements Of Operations And Comprehensive (Loss) Income (Unaudited)
Condensed Interim Consolidated Statements Of Shareholder's Equity (Unaudited)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) (Tables)
Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details)
Acreage Arrangement And Amendments To Cbi Investor Rights Agreement And Warrants
Acreage Arrangement And Amendments To Cbi Investor Rights Agreement And Warrants - Additional Information (Details)
Amounts Receivable, Net
Amounts Receivable, Net (Tables)
Amounts Receivable, Net - Additional Information (Details)
Amounts Receivable, Net - Components Of Amounts Receivable, Net (Details)
Asset Impairment And Restructuring Costs
Asset Impairment And Restructuring Costs - Additonal Information (Details)
Basis Of Presentation
Cash And Cash Equivalents
Cash And Cash Equivalents (Tables)
Cash And Cash Equivalents - Components Of Cash And Cash Equivalents (Details)
Debt
Debt (Tables)
Debt - Additional Information (Details)
Debt - Summary Of Components Of Debt (Details)
Debt - Summary Of Components Of Debt (Parenthetical) (Details)
Description Of Business
Equity Method Investments
Equity Method Investments (Tables)
Equity Method Investments - Summary Of Changes In Investments In Associates That Are Accounted For Using Equity Method (Details)
Equity Method Investments - Summary Of Financial Information Of Equity Method Investments (Details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (Tables)
Fair Value Of Financial Instruments - Additional Information (Details)
Fair Value Of Financial Instruments - Summary Of Financial Assets And Liabilities Measured At Estimated Fair Value On A Recurring Basis (Details)
Fair Value Of Financial Instruments - Summary Of Valuation Techniques And Significant Unobservable Inputs In The Fair Value Measurement Of Significant Level 2 Financial Instruments (Details)
Fair Value Of Financial Instruments - Summary Of Valuation Techniques And Significant Unobservable Inputs In The Fair Value Measurement Of Significant Level 3 Financial Instruments (Details)
Goodwill
Goodwill (Tables)
Goodwill - Changes In Carrying Amount Of Goodwill (Details)
Income Taxes
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Details)
Intangible Assets - Summary Of Components Of Intangible Assets (Details)
Inventory
Inventory (Tables)
Inventory - Additional Information (Details)
Inventory - Components Of Inventory (Details)
Noncontrolling Interests
Noncontrolling Interests (Tables)
Noncontrolling Interests - Summary Of Net Change In Noncontrolling Interests (Details)
Other Accrued Expenses And Liabilities
Other Accrued Expenses And Liabilities (Tables)
Other Accrued Expenses And Liabilities - Components Of Other Accrued Expenses And Liabilities (Details)
Other Financial Assets
Other Financial Assets (Tables)
Other Financial Assets - Summary Of Changes In Other Financial Assets (Details)
Other Income (Expense), Net
Other Income (Expense), Net (Tables)
Other Income (Expense), Net - Schedule Of Other Income (Expense), Net (Details)
Other Liabilities
Other Liabilities (Tables)
Other Liabilities - Components Of Other Liabilities (Details)
Pharmhouse
Pharmhouse - Additional Information (Details)
Pharmhouse - Other Financial Assets, Including Loans Receivable - Additional Information (Details)
Pharmhouse - Pharmhouse Equity Method Investment - Additional Information (Details)
Pharmhouse - Pharmhouse Financial Guarantee - Additional Information (Details)
Prepaid Expenses And Other Assets
Prepaid Expenses And Other Assets (Tables)
Prepaid Expenses And Other Assets - Components Of Prepaid And Other Assets (Details)
Property, Plant And Equipment
Property, Plant And Equipment (Tables)
Property, Plant And Equipment - Additional Information (Details)
Property, Plant And Equipment - Schedule Of Components Of Property, Plant And Equipment (Details)
Redeemable Noncontrolling Interest
Redeemable Noncontrolling Interest (Tables)
Redeemable Noncontrolling Interest - Summary Of Net Change In Redeemable Noncontrolling Interests (Details)
Revenue
Revenue (Tables)
Revenue - Additional Information (Details)
Revenue - Summary Of Disaggregation Of Revenue (Details)
Segment Information
Segment Information (Tables)
Segment Information - Additional Information (Details)
Segment Information - Summary Of Financial Information For Canopy Rivers (Details)
Share Capital
Share Capital (Tables)
Share Capital - Additional Information (Details)
Share Capital - Summary Of Issuances Of Stock Other (Details)
Share Capital - Summary Of Warrants (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation - Additional Information (Details)
Share-Based Compensation - Summary Of Assumptions Applied To Establish Fair Value Of Options Granted Using Black-Scholes Option Pricing Model (Details)
Share-Based Compensation - Summary Of Change In Seed Capital Options (Details)
Share-Based Compensation - Summary Of Changes In Canopy Rivers' Stock Options (Details)
Share-Based Compensation - Summary Of Outstanding Stock Options (Details)
Share-Based Compensation - Summary Of Share-Based Compensation Expense Related To Acquisition Milestones (Details)
Share-Based Compensation - Summary Of The Changes In Omnibus Plan Employee Options (Details)
Share-Based Compensation - Summary Of The Changes In Options Outstanding Under The Omnibus Plan (Details)
Share-Based Compensation - Summary Of The Changes In Rsus (Details)
Short-Term Investments
Short-Term Investments (Tables)
Short-Term Investments - Additional Information (Details)
Short-Term Investments - Components Of Short-Term Investments (Details)
Subsequent Events
Summary Of Significant Accounting Policies (Policies)
Ticker: CGC
CIK: 1737927
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-052540
Submitted to the SEC: Mon Nov 09 2020 4:31:32 PM EST
Accepted by the SEC: Mon Nov 09 2020
Period: Wednesday, September 30, 2020
Industry: Medicinal Chemicals And Botanical Products

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/cgc/0001564590-20-052540.htm